Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
home:diseases:celiac [07.19.2019]
sallieq [recent research]
home:diseases:celiac [07.20.2019] (current)
sallieq [recent research]
Line 69: Line 69:
  
 In 2015 I saw that 6 individuals in the USA were suing maker of Benicar. (//​presumably for bowel immunopathology caused by cytokines//​). //Somewhere else I found that 1.9 million individuals are currently taking Olmesartan Medoxomil.// ​ //6 in 1.9 million ? Seems pretty rare to me.// (//​Editor//​) In 2015 I saw that 6 individuals in the USA were suing maker of Benicar. (//​presumably for bowel immunopathology caused by cytokines//​). //Somewhere else I found that 1.9 million individuals are currently taking Olmesartan Medoxomil.// ​ //6 in 1.9 million ? Seems pretty rare to me.// (//​Editor//​)
 +
 +Gluten in "​gluten-free"​ manufactured foods in Australia: a cross-sectional study. ​ (({{pubmed>​long:​30404591}})) PMID 30404591
 +
  
 2018 data show that OLM is an Nrf2 activator, NFkB inhibitor and apoptosis inhibitor in an experimental model of ulcerative colitis. Overall, the study indicates that OLM shows promise as a potential therapy for the treatment of human inflammatory bowel diseases. ​ 2018 data show that OLM is an Nrf2 activator, NFkB inhibitor and apoptosis inhibitor in an experimental model of ulcerative colitis. Overall, the study indicates that OLM shows promise as a potential therapy for the treatment of human inflammatory bowel diseases. ​
home/diseases/celiac.txt · Last modified: 07.20.2019 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.